



PRESS RELEASE

EDEN BIODESIGN APPOINTS ROGER LIAS AS PRESIDENT EDEN BIODESIGN, USA

Liverpool, UK; 5th November 2007: Eden Biodesign Ltd, an expert provider of development and manufacturing services for new biopharmaceutical medicines, announced today the appointment of Dr Roger Lias as President Eden Biodesign, USA. Roger has extensive experience in the biotechnology industry with a specific emphasis on biomanufacturing services. Roger's responsibilities will include identifying and establishing strategic business partnerships and expanding Eden Biodesign's offer to the large US biopharmaceutical sector.

"I am delighted that Roger has joined Eden Biodesign. Roger's appointment will be pivotal in boosting our global business strategy," commented Eden Biodesign's Chief Executive Officer, Dr Crawford Brown. "His proven expertise and international experience will be a tremendous asset for Eden Biodesign as we seek to build our US infrastructure and expand our services to clients in the US market".

Roger Lias joins Eden Biodesign from Cytovance Biologics, where he has held the position of Vice President, Sales and Business Development since 2004, assuming responsibility for the entire commercial function. During this period he built the company's infrastructure, marketing programs and the initial customer base. At KBI BioPharma, a start-up contract biomanufacturing company, Roger played an active role in securing funding and building revenues. His responsibilities also included identifying and establishing strategic business partnerships and establishing new business relationships. Prior to that he was Vice President, Business Development at Diosynth where he had global responsibility and previously headed North American sales and marketing for Lonza Biologics. In both cases Roger was instrumental in generating substantial revenue growth.

"I am excited about joining the highly experienced Eden Biodesign team," Roger Lias said, "this position will allow me to contribute at a high level using the skills, experience and relationships I've acquired over the course of my career to establish a US based operation and significantly strengthen Eden Biodesign's position in the North American market. I believe that by offering high quality process development and manufacturing services supporting all major biopharmaceutical production systems, Eden Biodesign adds significant value and meets previously unmet market need."

Ends



For further information contact:

Sylvie Berrebi, DeFacto Communications Ltd +44 (0)20 7861 3838

Email s.berrebi@defacto.com

Notes to editors:

Eden Biodesign

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit www.edenbiodesign.com.